Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
NCT ID: NCT06310759
Last Updated: 2025-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2024-01-08
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
NCT00872495
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
NCT05796375
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has been scheduled for cystoscopy to rule out urothelial cancer
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University
OTHER
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jussi Nikkola
Role: PRINCIPAL_INVESTIGATOR
Tampere University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jesse Brown Department Of Veterans Affairs Medical Center
Chicago, Illinois, United States
Vancouver Prostate Centre
Vancouver, British Columbia, Canada
Helsinki University Hospital
Helsinki, , Finland
Satasairaala Hospital
Pori, , Finland
Seinäjoki Central Hospital
Seinäjoki, , Finland
Tampere University Hospital and Tampere University
Tampere, , Finland
Turku University Hospital
Turku, , Finland
Kindai University Hospital
Osaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Joel Cornfield
Role: primary
Peter Black
Role: primary
Tuomas Jalanko
Role: primary
Riikka Järvinen
Role: backup
Marjo Seppänen
Role: primary
Henry Haapiainen
Role: primary
Jussi Nikkola
Role: primary
Thea Veitonmäki
Role: backup
Pertti Nurminen
Role: primary
Peter Boström
Role: backup
Kazutoshi Fujita
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R21088B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.